Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of Padsevonil for focal-onset seizures in drug-resistant epilepsy
2017-003241-26Phase 2Unknown
- Sponsor
- UCB
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of padsevonil in Focal Onset Epilepsy and Focal onset seizure, sponsored by UCB. Primary endpoint: Incidence of treatment-emergent adverse events. Status: unknown.
02
Drugs
padsevonil
03
Conditions
Focal Onset EpilepsyFocal onset seizure
Beyond the preview
Go deeper on 2017-003241-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003241-26.